Although the clinical relevance of this combination remains to be clarified in colorectal cancer, in ER+/HER2- breast cancer, the PIK3CA activating mutation/low mTORC1 signaling was associated with better clinical outcomes to adjuvant ER-modulator (tamoxifen) treatment [21]. This evidence concerns the gene ERBB2 and breast carcinoma.